Mabwell (Shanghai) Bioscience (HKG:2493, SHA:688062) has received regulatory approval in China and the U.S. to begin clinical trials of 9MW5211, which targets inflammatory bowel disease (IBD), according to a Thursday filing with the Hong Kong bourse.
The company's Hong Kong shares fell over 1% in morning trade Friday.
Sichuan Biokin Pharmaceutical (SHA:688506) completed the enrollment of its first subject in the Phase III clinical trial on BL-M05D1 injection, according to a Shanghai bourse filing on Friday.The drug is being tested as a treatment for patients with Claudin18.2-positive advanced gastric cancer or gastroesophageal junction adenocarcinoma who have previously received first-line therapy.
TES (KOSDAQ:095610) secured a semiconductor manufacturing equipment contract from chipmaker SK Hynix (KRX:000660), the South Korean manufacturer of chips, solar cell, and display equipment, said in a Friday filing with the Korea Exchange.The contract, valued at 21.2 billion won, is valid until Jan. 15, 2027.Shares of SK Hynix fell nearly 7% in recent trade.
GuocoLand's (SGX:F17) Malaysia-listed unit, declined (Malaysia) (KLSE:GUOCO), filed a formal petition with the High Court of Malaysia to confirm its proposed share capital reduction and repayment framework, according to a Thursday filing.The court application, submitted on June 4, serves as the primary legal step remaining to execute the company's privatization via a selective capital reduction mechanism.This follows the property developer's shareholders approving the proposed privatization of the company at an extraordinary general meeting held on May 29.